Drug Development Pipeline

Kiromics therapies in development:

Kiromic Programs
BLADE-SMART
Immune System
Activating
Compounds
 
 
BSK01
BSK02 – ODP
Initial Indications Resarch Preclinical Validation pre-IND IND Phase I/II Clinical Trial
Acute Myeloid Leukemia (AML)
Solid Tumors
Kiromic Programs
BLADE-SMART
Immune System
Activating
Compounds
Initial Indication Phase
BSK01
Acute Myeloid Leukemia (AML)
Phase I/II Clinical Trial
BSK02 – ODP
Solid Tumors
IND
*ODP = Oral Delivery Platform / Orphan Drug Designation for ovarian cancer awarded June, 2016

Our immuno-oncology therapies are designed to successfully destroy cancer cells, while allowing healthy cells to remain unharmed. Our therapies are able to accomplish this goal by targeting substances specifically expressed by cancer cells. Kiromic’s efforts have led to the identification of two classes of cancer biomarkers that serve as targets to develop new cancer therapies: immunotargets and inhibitors. The advantage of using these cancer-specific targets includes improved efficacy and lower toxicity (i.e., fewer side effects), compared to currently approved cancer treatments.

For information of Kiromic BioPharma’s clinical trials, please visit: https://clinicaltrials.gov/ct2/results?term=kiromic&Search=Search

Kiromic’s immunotherapeutics hold a great potential to cure several solid tumors and leukemias. I am sure that clinical trials will show a significant benefit for many patients.

– Ruggero De Maria, MD | President of the Alliance Against Cancer
Copyright © 2018 Kiromic. All rights reserved.